Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma

NCT05705531 · View on ClinicalTrials.gov ↗

Study Summary

This study assesses how blood cell growth patterns (clonal hematopoiesis) relate to heart health or cardiovascular disease (CVD) after treatment in patients with Hodgkin lymphoma. In some patients, cancer treatment at a young age may lead to later complications, including problems with heart health. Checking for blood cell growth patterns called therapy-related clonal hematopoiesis (t-CH) can help predict who might be at risk for heart health problems after Hodgkin lymphoma treatment. If doctors know who may be at greater risk for developing later heart complications, then they can more closely monitor those patients to prevent or detect heart complications early.

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Magnetic Resonance Imaging
  • OTHER Survey Administration
  • OTHER Electronic Health Record Review
  • PROCEDURE Archive Sample Retrieval

Study Locations (20)

Florida

  • Golisano Children's Hospital of Southwest Florida — Fort Myers
  • Arnold Palmer Hospital for Children — Orlando
  • Saint Joseph's Hospital/Children's Hospital-Tampa — Tampa

New York

  • Albany Medical Center — Albany
  • Roswell Park Cancer Institute — Buffalo

Ohio

  • Cincinnati Children's Hospital Medical Center — Cincinnati
  • Nationwide Children's Hospital — Columbus

Alabama

  • USA Health Strada Patient Care Center — Mobile

Arizona

  • Phoenix Childrens Hospital — Phoenix

Connecticut

  • Yale University — New Haven

Delaware

  • Alfred I duPont Hospital for Children — Wilmington

Georgia

  • Children's Healthcare of Atlanta - Arthur M Blank Hospital — Atlanta

Trial Details

FieldValue
Enrollment Target 190 participants
Start Date 2023-08-18
Est. Completion 2028-10-01

Sponsor

Children's Oncology Group

318 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05705531

The ClinicalTrials.gov registry entry for NCT05705531 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 318 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Classic Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions — of which Biospecimen Collection is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05705531 reports 20 study locations spanning 16 distinct geographic areas — top geographies include Florida, New York, Ohio. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05705531 about?

NCT05705531 is a clinical study titled "A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma". This study assesses how blood cell growth patterns (clonal hematopoiesis) relate to heart health or cardiovascular disease (CVD) after treatment in patients with Hodgkin lymphoma. In some patients, cancer treatment at a young age may lead to later complications, including problems with heart health....

What is the current status of trial NCT05705531?

This trial is currently recruiting. The enrollment target is 190 participants. The study started on 2023-08-18. Estimated completion is 2028-10-01.

What conditions does trial NCT05705531 study?

This clinical trial studies the following conditions: Classic Hodgkin Lymphoma, Clonal Hematopoiesis, Cardiovascular Disorder. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05705531?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Survey Administration (OTHER), Electronic Health Record Review (OTHER), Archive Sample Retrieval (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05705531?

This trial is sponsored by Children's Oncology Group, which has 318 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05705531 being conducted?

This trial has 20 study locations across Alabama, Arizona, Connecticut, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial